ADMA BIOLOGICS (ADMA) SEC Filings

ADMA Biologics, Inc. director and officer Adam S. Grossman’s notice lists 189,000 common shares to be sold, with an aggregate market value of $1,980,720. It covers sales effected on November 5, 2026, and proposed sales during the subsequent 90-day period of up to 135,000 shares acquired or to be acquired through stock-option exercises and up to 54,000 shares from vesting and settlement of restricted stock units.

Up to 30,000 option shares covered by the notice would be acquired upon exercises connected with proposed future sales; acquisition and payment dates for those shares are the applicable exercise and sale dates.

ADMA Biologics, Inc. reported third-quarter 2026 revenue of $141.102 million, versus $134.224 million a year earlier, and net income of $49.884 million, versus $36.428 million. ASCENIV revenue was $124.742 million, compared with $95.410 million; diluted earnings per share were $0.22, versus $0.15.

For the first nine months, net income was $133.034 million, versus $97.551 million in 2025, while operating cash flow was $105.156 million, versus $14.757 million. Cash was $124.555 million at September 30, 2026. ADMA sold three plasma centers for $12.0 million and recognized an approximately $8.0 million gain.

ADMA borrowed $125.0 million under the JPMorgan revolving facility to fund an accelerated share repurchase; treasury-stock acquisitions used $180.300 million in nine-month financing cash flow. Total debt was $195.857 million at September 30, 2026, versus $72.143 million at December 31, 2025. For SG-001, ADMA said the FDA gave constructive feedback in October 2026 on the pre-IND package; the agency said the proposed assay would be acceptable subject to appropriate validation, and ADMA plans to incorporate recommendations into its clinical protocol.

ADMA Biologics reported third-quarter 2026 revenue of $141.1 million, up 5.1% year over year, and GAAP net income of $49.9 million, up approximately 37%. ASCENIV revenue was $124.7 million, up 31%; Adjusted EBITDA, a non-GAAP measure, was $77.3 million, up 32%, and gross margin was 71%, compared with 56% a year earlier.

ADMA also reported $15.4 million in third-quarter revenue against $19.4 million in the second quarter, citing competitive pricing and channel inventory pressures in the standard immune globulin market. It repurchased 2.7 million shares in the quarter and 16.5 million year to date through September 30, equal to 6.3% of common stock outstanding as of December 31, 2025.

ADMA reiterated FY2026 total revenue guidance of at least $530 million and increased its minimum outlooks for Adjusted Net Income to $180 million and Adjusted EBITDA to $275 million. The FDA provided constructive feedback on SG-001's pre-IND package; ADMA intends to incorporate the recommendations into the clinical protocol and prepare an IND submission. The proposed assay would be acceptable for product testing, subject to appropriate validation.

State Street Corporation and its affiliate SSGA Funds Management, Inc. report significant passive ownership of ADMA Biologics common stock as of June 30, 2026. State Street beneficially owned 17,116,022 shares, representing 7.4% of the common stock, with 16,375,576 shares subject to shared voting power and all 17,116,022 shares subject to shared dispositive power; they report no sole voting or dispositive power. Within this, SSGA Funds Management beneficially owned 11,593,203 shares, or 5% of the class, all on a shared voting and dispositive basis. The filing identifies several State Street Global Advisors entities as investment adviser subsidiaries through which the holdings are managed and states that no other person is known to have rights to more than 5% of the dividends or sale proceeds for these securities.

ADMA Biologics reported second quarter 2026 results showing modest top-line growth but significantly higher profitability, driven by ASCENIV. Total revenue for the quarter ended June 30, 2026 was $124.4 million, up 2% year-over-year. ASCENIV revenue rose to $102.9 million, a 24% increase, while revenue from another immune globulin product declined 49% year-over-year but improved sequentially from first-quarter trough levels. Gross profit was $86.3 million with a 69% gross margin, compared with 55% a year earlier, reflecting a richer ASCENIV mix and a yield‑enhanced manufacturing process.

GAAP net income for the quarter was $37.8 million and GAAP basic EPS was $0.17, up 11% and 17% year-over-year, respectively. Adjusted net income was $39.0 million and Adjusted EBITDA $61.8 million, up 8% and 22% year-over-year. For the first half of 2026, revenue was $238.9 million; GAAP net income was $83.1 million and Adjusted EBITDA $121.5 million. Cash and cash equivalents increased to $136.0 million at June 30, 2026, supported by $87.8 million of net cash provided by operating activities, alongside substantial share repurchases and higher long‑term debt. The company reiterated its FY2026 financial guidance and highlighted real‑world data from 127 ASCENIV‑treated patients showing reduced infection‑related hospitalizations and healthcare utilization.

ADMA Biologics executive Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance, reported a tax-withholding disposition of 3,177 shares of common stock at $8.37 per share to satisfy mandatory taxes on vested RSUs. This was not an open-market sale. After the transaction she directly owned 443,061 shares, in addition to multiple unvested RSU grants that will settle into common stock as they vest.

ADMA Biologics CFO and Treasurer Terry Kohler received equity awards on July 16, 2026. He was granted 85,130 restricted stock units (RSUs) that vest over four years, bringing his unvested RSUs to 143,149, including 58,019 from a December 8, 2025 grant. He also received a stock option for 136,363 shares of common stock at an exercise price of $8.81 per share, vesting 25% after one year and the remainder in substantially equal monthly installments through July 16, 2030, with an expiration date of July 16, 2036.

ADMA Biologics, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on June 2, 2026. As of the April 8, 2026 record date, 232,324,283 common shares were outstanding, and 199,267,547 shares were represented virtually or by proxy, constituting a quorum.

Stockholders elected Class I directors Alison C. Finger and Eduardo Rene Salas. Finger received 156,849,830 votes for and 19,376,842 votes withheld, with 23,040,875 broker non-votes. Salas received 171,947,523 votes for and 4,279,149 votes withheld, with the same broker non-votes.

Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 198,655,040 votes for, 329,056 against, and 283,451 abstentions. On a non-binding advisory basis, the Say-on-Pay proposal for named executive officer compensation was approved, receiving 168,169,866 votes for, 7,730,690 against, 326,116 abstentions, and 23,040,875 broker non-votes.